SB 657510 may be used to study the urotensin II receptor-mediated signaling.
Azioni biochim/fisiol
SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist.
SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1
SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.
Caratteristiche e vantaggi
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed. Endothelial cells were grown in normal- and high-glucose (5 and 25 mmol/l) media with and without UII
Domande
Recensioni
★★★★★ Nessuna valutazione
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..